Corcept Therapeutics Incorporated, fundada en 1998 y con sede en Menlo Park, California, es una empresa farmacéutica dedicada al descubrimiento, desarrollo y ...
Corcept Therapeutics Incorporated (NASDAQ: CORT), headquartered in Redwood City, California, was founded in 1998 and has been a pioneer in cortisol modulation, a therapeutic approach targeting the glucocorticoid receptor (GR). The company's flagship product, Korlym (mifepristone), received FDA approval in 2012 for the treatment of hyperglycemia secondary to hypercortisolism in ...Corcept Therapeutics Incorporated (NASDAQ: CORT), headquartered in Redwood City, California, was founded in 1998 and has been a pioneer in cortisol modulation, a therapeutic approach targeting the glucocorticoid receptor (GR). The company's flagship product, Korlym (mifepristone), received FDA approval in 2012 for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed or are not candidates for surgery. This first-in-class medication blocks the effects of cortisol at the GR, addressing the underlying hormonal imbalance in this rare endocrine disorder.
Beyond Korlym, Corcept has a substantial pipeline, with lead candidate relacorilant, a selective cortisol modulator, under investigation for Cushing's syndrome, as well as in combination with nab-paclitaxel for advanced ovarian cancer, having completed Phase II trials. The company is also developing other selective cortisol modulators for conditions such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain. Additionally, it is exploring FKBP5 gene expression assays as potential biomarkers.
Financially, Corcept has demonstrated strong commercial execution, with revenues primarily driven by Korlym. The company maintains a solid balance sheet with no significant debt and ample cash reserves to fund its research and development activities. It employs approximately 730 full-time staff and is led by CEO and co-founder Dr. Joseph K. Belanoff, who has been at the helm since its inception. The company is committed to unlocking the therapeutic potential of cortisol modulation to treat serious metabolic, oncologic, and neuropsychiatric disorders, reflecting a long-term vision for addressing unmet medical needs.
Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal
InteranualYoY significa Year-over-Year (interanual). Compara el último valor anual con el valor anual anterior para mostrar la fortaleza de la tendencia a largo plazo.
TrimestralQoQ significa Quarter-over-Quarter (intertrimestral). Compara el último trimestre con el trimestre inmediatamente anterior para mostrar cambios de impulso a corto plazo.
IngresosEl dinero total que entró por la puerta principal al vender cosas, antes de pagar una sola factura. Piensa en esto como el gran total de cada compra con tarjeta de los clientes. (YoY compara el rendimiento de este año con el del año pasado, mientras que QoQ compara los tres meses actuales con los tres anteriores).
$761.4M
+12.8%
+55.3%
Beneficio netoEl resultado final absoluto. Si la empresa pagara a cada proveedor, empleado, banquero y recaudador de impuestos, este es el dinero real que queda en su bolsillo al final del día.
$99.7M
-28.7%
+235.1%
Margen brutoEl margen básico. Si venden unas zapatillas de 100 dólares, este porcentaje indica cuánto de ese precio es ganancia justo después de pagar el caucho y los cordones, pero antes de pagar el alquiler de la tienda o los anuncios de televisión.
+98.3%
-0.1%
+0.2%
Margen operativoLa puntuación de eficiencia del 'trabajo diario'. De cada dólar que gasta un cliente, esto muestra cuántos centavos mantiene la empresa después de fabricar el producto Y pagar todos los gastos generales corporativos (como salarios, marketing y mantener las luces encendidas).
+5.9%
-71.0%
+153.6%
Margen netoEl porcentaje final que se lleva a casa. Cuando se eliminan todos los costos concebibles, impuestos y pagos de intereses, este es el número exacto de centavos que la empresa realmente se queda de cada dólar en ventas.
+13.1%
-36.8%
+186.9%
Flujo de caja libreEl santo grial del efectivo corporativo. Es el dinero físico gastable que queda después de que el negocio paga sus operaciones diarias Y compra las actualizaciones grandes y costosas (como nuevas fábricas o servidores) que necesita para sobrevivir. Este es el dinero 'libre' que pueden usar para pagar dividendos o recomprar acciones.
$141.8M
-27.6%
+282.7%
Margen FCFLa tasa definitiva de conversión de efectivo. Muestra qué tan buena es la empresa para convertir ventas regulares directamente en efectivo frío, duro y gastable. Un porcentaje alto significa que el negocio es una auténtica máquina de imprimir dinero.
+18.6%
-35.8%
+217.6%
Deuda/PatrimonioEl indicador de riesgo financiero. Compara cuánto del imperio de la empresa se construyó con dinero prestado (préstamos) frente al dinero propio de los propietarios (accionistas). Un número alto significa que están muy apalancados y juegan un juego más arriesgado; un número bajo significa que juegan a lo seguro.
0.9%
-7.6%
-11.6%
Ratio corrienteLa verificación de supervivencia de 12 meses. Simplemente compara el efectivo que tienen ahora mismo (más cosas que pueden convertirse rápidamente en efectivo) con las facturas inmediatas que absolutamente deben pagar este año. Una puntuación superior a 1 significa que tienen suficiente en la billetera para cubrir las próximas facturas sin entrar en pánico.
2.92x
-12.7%
+0.1%
Activos totalesEl tamaño absoluto del imperio de la empresa. Agrupa absolutamente todo lo valioso que poseen, desde el efectivo en la caja registradora y el inventario en el almacén, hasta las patentes de software en la bóveda y las fábricas en el suelo.
Operator: Thank you for standing by, and welcome to the Corcept Therapeutics Second Quarter 26 Earnings Conference Call. At this time, participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press *1 on your telephone. If your question has been answered and you would like to remove yourself from the queue, simply press *1 again. As a reminder, today's program is being recorded. And now I would like to introduce your host for today's program, Atabak Mokari, CFO. Please go ahead, sir.
Atabak Mokari: Hello, everyone. Good afternoon, and thank you for joining us. Today, we issued a press release announcing our financial results for the second quarter and providing a corporate update. A copy is available at corcept.com. Our complete financial results will be available when we file our Form 10-Q with the SEC. Today's call is being recorded. A replay will be available at the Investors Past Events tab of our Statements during this call other than statements of historical fact are forward looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those such statements expressed or imply. The risks and uncertainties that may affect our forward looking statements are described in our annual report on Form 10-K and our quarterly reports on Form 10-Q which are available at the SEC's website. Please refer to those documents for more information. We disclaim any intention or duty to update forward looking statements. Our revenue in the second quarter of 26 was $256 million a 32% increase over the prior year period. Korlym and authorized generic product revenue were $208.6 million Lifyorli product revenue was $47.6 million in its first quarter of availability. We expect growth to continue and have increased our 2026 revenue guidance to a range of $1.1 billion to $1.2 billion Net income was $43 million in the second quarter of 26, compared to net income of $35 million in the prior year period. Please note that our operating expenses in the second quarter were flat to the first quarter of 26. Our cash and investments at June 30 were $545 million. I will now turn the call over to Sean Maduck, president of our endocrinology division. Sean?
Sean Maduck: Thanks, Atabak. Our Cushing's syndrome business continues to experience strong demand. The second quarter saw a record number of new prescriptions and first time prescribers. We have never had more patients receiving our medications or more active prescribers. Our growth is due to physicians increasing awareness that hypercortisolism is a serious disease that is more prevalent than previously understood. Hypercortisolism is underdiagnosed because its signs and symptoms, such as difficult-to-treat diabetes or resistant hypertension, are the same as those of other more common conditions. Tens of …
